tafamidis meglumine
tafamidis meglumine is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Vyndaqel. Available dosage form: capsule, liquid filled.
Drug Details
- Generic Name
- tafamidis meglumine
- Brand Names
- Vyndaqel
- Application Number
- NDA211996
- Sponsor
- Pfizer Laboratories Div Pfizer Inc
- NDC Codes
- 1
- Dosage Forms
- CAPSULE, LIQUID FILLED
- Routes
- ORAL
- Active Ingredients
- TAFAMIDIS MEGLUMINE
Indications and Usage
1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )